MFN News Items – Page 2

Strong Start to 2025 – iZafe Group Accelerates Dosell’s Growth

2025 has started on a positive note for iZafe Group, with steady growth in Dosell and increasing demand across multiple markets. To provide better insights into our journey and progress, we are launching a monthly newsletter to share more frequent updates on developments behind the scenes.

If you are not yet receiving these updates via email, be sure to subscribe at the bottom of our website or through the link in our latest LinkedIn post. Follow us on LinkedIn for continuous updates.

Continuous Growth and Key Milestones
The number of billable Dosell units increased by 25% from December to January, a clear sign that our strategy and partnerships are driving demand.

Our growth is still from a smaller scale, but it is steadily increasing, bringing us closer to a key milestone of 1,000 active Dosell units in use. We expect to reach this soon, marking a significant step in our expansion.

Our business model is based on partners purchasing and stocking Dosell, ensuring cost coverage at the time of sale. The long-term value is generated when the units are activated, creating a recurring monthly revenue stream.

We have already shipped 2,500 Dosell units to our partners, who are experiencing strong demand and expect to activate them within 3–6 months. This increasing activation rate drives our revenue stream, creating a stable and scalable business model.

Sweden: Strong Momentum in VGR and More Municipalities Adopting Dosell
Dosell usage in Västra Götaland Region (VGR) has increased by 18% since December, and interest from municipalities continues to grow. We now have seven new municipalities scheduled for implementation in Q1, both within and outside VGR.

Our partners are actively driving Dosell through existing framework agreements, which accelerates deployment. To meet rising demand and support municipalities with implementation, we will host a webinar for VGR municipalities on March 6 in collaboration with ATEA.

At the MVTe trade fair, Dosell continued to generate strong interest from municipalities and private healthcare providers. Several follow-up meetings are scheduled in February.

Here are just a few comments from Swedish municipal staff, caregivers, and users about Dosell:

"We placed a Dosell with a user who was very skeptical at first. But after just a few days, she was thrilled that she could manage her medication independently while knowing that home care had full control in case she forgot."

"Our municipal staff was highly impressed after seeing Dosell presented. Compared to the larger, more complicated devices we previously used, Dosell will greatly simplify daily work."

"It is so easy to learn!"

"Using Dosell was the best decision we made. My father feels secure, and I receive alerts if anything deviates."

"When many other things started to become difficult due to memory loss, medication management continued to function thanks to Dosell."

Norway: Faster Implementation Through Partnerships
In Norway, we have partnered with Randstad to accelerate implementations and ensure optimal Dosell usage throughout contract periods.
In January, we conducted a comprehensive training session with Hepro, Careium AS, and Randstad to ensure a smooth rollout and equip their sales teams with the right tools for driving adoption.

Netherlands: Stable and Long-Term Growth
The Netherlands continues to be a key market with steady growth in Dosell adoption. Our partner has successfully integrated Dosell into its own platform, "Dispenze", which has been highly appreciated by customers. More organizations are now replacing competing solutions with Dosell.

A testament to our partner’s long-term commitment is their investment in a Dosell showroom, office, and branded delivery vehicles.

Follow TCCN on LinkedIn for regular insights and updates on how Dosell is used in the Netherlands.

Spain: Launch Around the Corner
Ti-medi has developed a comprehensive system and e-commerce solution to ensure a successful Dosell launch in Spain. The process has taken longer than expected, but we anticipate the launch happening in February.

Product Development: Improvements Drive Demand
Over the past year, we have released 13 software versions, and we are soon launching version 14, which includes significant enhancements.

Our goal has always been clear: Dosell should be simple and reliable for users, while we continuously improve refill processes, integrations, and the overall experience for caregivers and partners.

These ongoing improvements have been key to the growth we see today. Dosell is now more efficient than ever, which in turn drives increased demand.

Capital Raise and Focus on Profitability
We would also like to take this opportunity to thank our major shareholders for their support in the directed share issue of approximately SEK 9.2 million.

This capital injection strengthens our ability to accelerate growth while maintaining a clear focus on cost efficiency and achieving cash flow profitability.

We look forward to sharing more details in our upcoming quarterly report next week – stay tuned!

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Strong Start to 2025 – iZafe Group Accelerates Dosell's Growth

Kvartalsrapport

iZafe Group AB has completed a directed share issue of B shares amounting to approximately SEK 9.2 million

The Board of Directors of iZafe Group AB (“iZafe” or the “Company”) has today, based on the authorization granted by the Annual General Meeting on May 30, 2024, resolved on a directed share issue of 46,150,000 B shares at a subscription price of SEK 0.20 per B share (the “Directed Share Issue”). Through the Directed Share Issue, the Company will raise approximately SEK 9.2 million before deductions for set-offs and transaction-related costs. The Directed Share Issue was targeted at a group of Swedish and international investors, including Gästrike Nord Invest AB, WARDCO Invest AB, the Spanish partner JUNIORFARMA S.L., and Exelity AB.

The Directed Share Issue
The Board of Directors of iZafe has today resolved to carry out a directed share issue of 46,150,000 B shares at a subscription price of SEK 0.20 per B share, raising approximately SEK 9.2 million before loan set-offs and transaction-related costs. Loan set-offs amount to a total of approximately SEK 0.5 million. The Directed Share Issue was resolved based on the authorization granted by the Annual General Meeting on May 30, 2024. The subscription price of SEK 0.20 corresponds to a discount of approximately 5.2 percent compared to the volume-weighted average price (VWAP) of the Company’s share on Nasdaq First North Growth Market over the past ten (10) trading days up to and including January 13, 2025. The Directed Share Issue was targeted at a group of Swedish and international investors, including Gästrike Nord Invest AB, WARDCO Invest AB, the Spanish partner JUNIORFARMA S.L., and Exelity AB. The Company intends to use the net proceeds from the Directed Share Issue to strengthen its working capital to accelerate the Company’s continued growth.

The subscription price was determined through arm’s length negotiations between the Company and the subscribers, based on the current market price of iZafe’s share. The Directed Share Issue also provides an opportunity to capitalize on the current interest in the Company’s shares among the subscribers at a price aligned with the prevailing share price. Against this background, the Board considers the subscription price to reflect current demand and market conditions and, therefore, to be market-based.
The Directed Share Issue will increase the number of shares in iZafe by 46,150,000, from 275,586,171 to 321,736,171. The number of votes in the Company will increase by 46,150,000, from 280,986,171 to 327,136,171. The Company’s share capital will increase by SEK 9,230,000, from SEK 55,117,234.20 to SEK 64,347,234.20. The Directed Share Issue entails a dilution of approximately 14.3 percent of the total number of shares and approximately 14.1 percent of the total number of votes in iZafe.
The subscribers in the Directed Share Issue include several existing and long-term shareholders, such as Gästrike Nord Invest AB, WARDCO Invest AB, JUNIORFARMA S.L., Filippa Lindström, Eva Redhe, Fredrik Sjödin, Cecilia Kragsterman, and Pia Engholm, as well as new investors such as Exelity AB, Jimmie Landerman, and Klas Zetterman. The shares in the Directed Share Issue have been subscribed for and allocated.

Reason for Deviation from Shareholders’ Preferential Rights
The purpose of the Directed Share Issue and the reason for deviating from shareholders’ preferential rights is to conduct a capital raise in a time- and cost-efficient manner. The Board has evaluated the possibility of conducting a rights issue as a first option. After weighing the advantages and disadvantages of a rights issue compared to a directed share issue, the Board concluded that a rights issue (i) would be significantly more time-consuming, potentially causing the Company to miss out on growth opportunities, (ii) would result in substantially higher costs for the Company, primarily related to underwriting syndicates and legal expenses, (iii) would expose the Company to greater market volatility, and (iv) would likely need to be conducted at a lower subscription price, resulting in greater dilution, which would be detrimental to all shareholders.
The Directed Share Issue also provides an opportunity to capitalize on the current interest in the Company’s shares among the subscribers at a price aligned with the prevailing share price. Considering the above and after thorough deliberation, the Board has determined that the Directed Share Issue is the most advantageous financing option for iZafe and is in the interest of both shareholders and the Company.
The subscription price in the Directed Share Issue has been determined through arm’s length negotiations with the investors, based on the prevailing share price of the Company’s B shares. Additionally, the Board has ensured the subscription price’s market-based nature in consultation with financial advisors, considering current market conditions and previously indicated price levels in discussions with potential investors. According to the Board’s assessment, the market basis of the subscription price has been ensured through this procedure.
The inclusion of existing shareholders in the Directed Share Issue was both part of the negotiations with new investors and deemed strategically prudent by the Board to include these longstanding and committed shareholders in the Directed Share Issue.

Comment from iZafe’s CEO, Anders Segerström, on the Directed Share Issue:
“The Directed Share Issue is a strategic step to accelerate our growth and strengthen our market position. The strong interest from both Swedish and international investors reflects confidence in our vision to revolutionize medication management through innovative solutions like Dosell and Pilloxa. We look forward to continuing the development of our products and expanding our global reach.”

Subscribers in the Directed Share Issue:
Cecilia Kragsterman, Exelity AB, Eva Redhe, Filippa Lindström, Fredrik Sjödin, Gästrike Nord Invest AB, Jimmie Landerman, JUNIORFARMA S.L., Klas Zetterman, Pia Engholm, and WARDCO Invest AB.

Advisors
Partner Fondkommission AB acts as financial advisor and issuing agent in connection with the Directed Share Issue.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group AB has completed a directed share issue of B shares amounting to approximately SEK 9.2 million

Affärer Partners

The Year in Review: Reflections from iZafe Group’s CEO on 2024

2024 has been a transformative year for iZafe Group, where we have laid a strong foundation for the future. We have multiplied our net revenue, delivered over 500 Dosell units to Spain, and are approaching 2,000 units in the Netherlands. The number of units that deliver the right medication at the right time daily has increased by approximately 500% compared to 2023, confirming that our solutions meet market needs and create real value.

Our partners have purchased hardware with the expectation of implementing these units within a relatively short period, which strengthens our business model of generating recurring monthly revenue.

The launch of Dosell 3.0 marks a milestone with improved functionality and integration. At the same time, we have changed production partners and built efficient production workflows, making us ready to scale up production to meet increasing demand and ensure high quality in every delivery. This work has laid a solid foundation for continued success.

Our innovative efforts have led to several new integrations, such as with Enovation UMO, and strong collaborations with partners like TCCN in the Netherlands and Ti Medi in Spain. These advancements reinforce Dosell as a global leader in health technology, providing solutions that enhance safety and independence for both users and healthcare staff. In Sweden, we have successfully implemented Dosell in numerous municipalities. Our solutions have been appreciated for their user-friendliness, safety, and ability to prevent medication errors. This has not only improved user independence but also streamlined the work of healthcare professionals. This success underscores Dosell's central role in digitalizing and optimizing healthcare at the municipal level.

Looking Ahead to 2025 With a solid foundation in place, we look forward to accelerating our growth. Our pipeline is strong, and we expect 2025 to build on the successes of this year. We plan to further expand Dosell’s presence while giving Pilloxa a central role in our portfolio. These initiatives will enable more innovative solutions and strengthen our position as a leader in health technology. We aim to continue creating value for our customers and shareholders through sustainable and profitable growth.

Thank You for Your Support I would like to extend my heartfelt thanks to our employees, partners, and shareholders. It is through your dedication and commitment that we can continue building a brighter future for healthcare and for iZafe Group. We look forward to 2025 with great ambition and strong confidence in our shared potential.

With warmth and appreciation,
Anders Segerström CEO, iZafe Group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

The Year in Review: Reflections from iZafe Group’s CEO on 2024

Dosell Karta

iZafe Group AB Strengthens Global Position with UMO Certification for Dosell

iZafe Group AB announces that its product, Dosell, is now certified for integration with Enovation UMO, the monitoring solution for medical service centres. Enovation UMO is part of Enovation Platform, a leading platform for digital care and collaboration used in over 18 countries. This certification marks a significant milestone for iZafe and enables strategically important expansion in both established and new markets.

A Long-Awaited Solution for Dutch Partners
The certification has been highly anticipated by iZafe's partners in the Netherlands, where Enovation UMO is a well-established standard in healthcare. These partners have been eager to begin selling Dosell and can now leverage the seamless integration with the UMO platform. This ensures that Dosell not only complements but also enhances their offering by providing a comprehensive solution for medication management, alarms, and other digital healthcare services within the same platform.

"Creating a Unique Market Position"
"This certification is a critical milestone for iZafe and our partners, especially in the Dutch market, where interest in Dosell is substantial," says Anders Segerström, CEO of iZafe Group AB. "Dosell is specifically designed to be part of a healthcare technology ecosystem, and integrations like this not only simplify implementation but also improve the experience for both users and caregivers."

Benefits of an Integrated Ecosystem
By becoming certified on Enovation UMO, Dosell establishes a unique market position. Offering an integrated solution that handles medication management, alarms, and other care needs within a single platform meets the growing demand for comprehensive solutions in digital healthcare. This not only enhances iZafe's appeal to healthcare providers but also enables its partners to deliver a more competitive and value-driven offering to their customers.

Opening Doors to More Markets
Beyond the Netherlands, this integration also creates opportunities for iZafe to expand into other markets where Enovation UMO is established. With the platform’s presence in 18 countries, iZafe has a unique opportunity to strengthen its international presence and build relationships with new partners and customers.

A Step Forward for iZafe’s Growth Strategy
The certification is part of iZafe’s broader strategy to establish Dosell as a key component of the global healthcare technology landscape. By collaborating with established platforms like Enovation UMO, iZafe demonstrates its commitment to innovation and its ability to meet market demands for integrated and efficient healthcare solutions.

About Enovation Platform
Enovation UMO is part of the Enovation Platform: the leading platform for digital care and collaboration. With over 350 partners worldwide, the platform offers a wide variety of integrations. Enovation Platform uses open software, which connects seamlessly to care organisations' systems and those of their partner organisations. This way, the platform provides all the digital tools care professionals need to support patients or clients – whatever their needs.
https://enovationgroup.com/en/enovation-umo/

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group AB Strengthens Global Position with UMO Certification for Dosell

Enovation UMO Certified Partner

Dosell Secures Large Order for 1,000 Units in the Netherlands – Order Value of SEK 3 Million and Up to SEK 400,000/Month in Recurring Revenue

iZafe Group AB (publ) ("iZafe") announces today that it has received a new confirmed order for an additional 1,000 Dosell units from its exclusive distributor in the Netherlands, TCCN. This strategically important order has a value of approximately SEK 3 million. Deliveries will be split into two batches – 750 units in 2024 and the remaining 250 in the first half of 2025 – laying the foundation for stable licensing revenue of up to SEK 400,000 per month during 2025.

This order ensures that TCCN retains its exclusivity in the Dutch market, in accordance with previously communicated terms.

Once this order and previous ones are fully implemented, they are expected to generate recurring revenue of approximately SEK 400,000 per month in 2025. The order strengthens iZafe's cash flow and builds a long-term revenue model, clearly affirming Dosell's strong position as a leading solution in medication dispensing and a vital tool for the digitalization of the healthcare sector.

Since the beginning of the year, TCCN, which took over the exclusive distribution agreement for Dosell in the Netherlands, has established a dedicated office and showroom for Dosell in Assen. TCCN has successfully positioned Dosell in the rapidly growing Dutch medication dispensing market through partnerships with several leading players, including MobileCare.

"This order and the recurring revenue it generates demonstrate the enormous potential Dosell has to deliver both short-term results and long-term growth. We are impressed with TCCN’s work and view this development as a strategic milestone on our journey to making Dosell the leading solution for medication dispensing in Europe," says Anders Segerström, CEO of iZafe Group.

"The momentum for Dosell in the Dutch market is strong, both in the intramural and extramural market segments. With our gradual product introduction approach and focus on quality, we have built a solid foundation for TCCN’s new business unit. Our customers – healthcare providers for home care and intramural long-term care – appreciate the Dosell’s highly autonomous working, effortless deployment and low cost. We expect a strong growth going forward and this order enables us to meet the demand in the Dutch market during first half of 2025. " says Taeke Castelein, Managing Director of TCCN.

The Dutch market for medication dispensing solutions is in an expansive phase, where digital solutions are becoming increasingly central to improving patient safety and efficiency. Dosell meets these needs with its unique functionality that prevents double dosing and ensures correct medication intake. TCCN’s dedicated efforts have established Dosell as a strong player in this ecosystem, and continued implementation is expected to drive both market share and revenue growth.

For more information about TCCN, visit: https://tccn.eu.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.com

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Dosell Secures Large Order for 1,000 Units in the Netherlands – Order Value of SEK 3 Million and Up to SEK 400,000/Month in Recurring Revenue

Sjalvstandig Medicinering Hemtjanst 2

iZafe Group’s CFO, Marius Sandberg, purchases 177,793 shares

iZafe Group's CFO, Marius Sandberg, has today acquired 177,793 B-shares in the company at a value of SEK 34,909 (SEK 0.196 per share).

The acquisition was completed today, November 14, bringing Marius Sandberg's total shareholding in iZafe to 177,983 B-shares.
"As the new CFO, I see the potential that exists in iZafe, and with this share purchase, I am demonstrating my confidence in the company’s future. I look forward to being part of iZafe’s growth journey and to continue working towards creating value for our shareholders and contributing to the company’s long-term success," says Marius Sandberg, CFO of iZafe Group.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group's CFO, Marius Sandberg, purchases 177,793 shares

Grupp Kollegor På Möte

iZafe Group Q3 Interim Report, July-September 2024

iZafe Group AB (publ.) presents today, November 1, its report for the third quarter.

Financial Performance in Summary

Total revenue for the quarter amounted to 2,434 (927) TSEK, an organic growth approximately 2.5 times higher than the corresponding quarter of the previous year.

The operating result (EBIT) for the quarter amounted to -4,148 (-5,012) TSEK.

The operating profit before depreciation (EBITDA) for the quarter amounted to -3,166 (-3,159) TSEK.

The result after financial items for the quarter amounted to -4,955 (-5,004) TSEK.

The period’s cash flow from operating activities amounted to -2,913 (-2,854) TSEK.

Earnings per share for the quarter before / after dilution amounted to -0.02 (-0.02) SEK.

Equity per share at the end of the period amounted to 0.1 (0.2) SEK.

The solidity at the end of the period amounted to 58.0 (82.9) percent.

Significant events during the quarter

iZafe Group AB received an order for 500 Dosell units from its partner Ti Medi. This order is part of Ti Medi’s launch of a new concept, where Dosell is integrated with their dose-packaging machines to offer pharmacies a complete solution that improves patient medication adherence.

iZafe Group AB entered into a loan agreement for 5.5 MSEK with Exelity AB, which replaces the previous TO14B series warrants that were canceled due to high costs and uncertainty. The loan will be used to increase production volumes and intensify sales and marketing efforts, supporting the company’s long-term growth strategy.

iZafe Group AB has entered a three-party collaboration with Zafe Care Systems AB and Sensorem AB. The partnership combines Dosell with Sensorem’s safety alarms to enhance independence and safety in medication management, even outside the home, strengthening both freedom and quality of care in the healthcare sector.

iZafe Group AB has entered a partnership with Randstad in Norway to streamline the implementation of Dosell in Norwegian municipalities. Through Randstad’s presence and expertise in staffing, sustainable implementation and improved medication management are ensured, potentially leading to cost savings in healthcare.

Significant events after the end of the quarter

iZafe Group AB launched Dosell in Spain in collaboration with Ti Medi. At an event in Granada, Dosell was presented to Ti Medi’s network of 1,400 pharmacies. This launch marks an important milestone and signifies that Dosell is now commercially available in Spain, with the first units to be in use shortly. The collaboration aims to improve medication management and adherence among patients.

Comments from CEO
It is with great pleasure that I can state that we are in a very exciting and expansive phase. Our growth journey has truly gained momentum, and we are seeing clear results from our efforts to revolutionize healthcare through innovation and digitalization. The number of active units has increased by 29% compared to the previous quarter, and we have now delivered approximately 2,000 Dosell units to our partners. Our mission to digitalize healthcare and ensure the right medicine at the right time is starting to take shape in earnest.

Spain – A New Market with Great Potential
Earlier this year, we received an order for 500 Dosell units from our partner Ti Medi, and I am proud to announce that Ti Medi has now launched our innovative solution in the Spanish market. Together with Ti Medi and their 1,400 pharmacies, we are offering a unique solution that combines their dose-packaging machines with our medication robot, Dosell. This is a groundbreaking offering that will change how pharmacists monitor patient medication adherence, leading to better healthcare. This launch is our first major venture outside Sweden targeting the consumer market, and next year, we look forward to extending this offering to the healthcare sector as well.

New Phase – Clearer Forecasts and Increased Insight into Growth Potential
We are now entering a new and very important phase for iZafe Group. For the first time, we can forecast our growth based on actual key metrics, showing how the number of active Dosell units increases each month. This means that, starting from the next quarterly report, we will be able to present clear and credible forecasts that give you, our existing shareholders, and potential new investors, an even better understanding of the company’s future potential. This is an important milestone for us and something that will further strengthen our position moving forward.

More Markets and Continued Growth
Our expansion is not limited to Spain. We have seen strong demand from both Swedish municipalities and our international markets. The Netherlands and Sweden have continued to deliver steady growth, and we expect Norway and Finland to follow suit during the final quarter. Our business model is based on active units with recurring revenue, and we are working diligently to ensure that we can meet increasing demand and create steady growth month by month.

At the same time, our total revenue has tripled compared to the first three quarters of last year, further confirming the positive development.

Strategic Partnerships and Innovation
We have also taken an important step forward with our strategic three-party collaboration with Zafe Care Systems and Sensorem. Together, we offer a holistic solution for increased independence and security in medical care. Through the integration of Sensorem’s safety alarms with Dosell, we can ensure that users are reminded to take their medicine even when they are far from home, creating a safer daily life for those who rely on continuous medication. This is a strong symbol of our vision to create solutions that not only streamline healthcare but also give users greater freedom and security in their everyday lives.

Opportunities for the Future
We now look forward to further strengthening our presence, with more Dosell units being implemented in municipalities and healthcare institutions across Europe. Particularly exciting is our expansion in Norway, where we have entered into a partnership with Randstad to ensure an efficient and successful implementation of our solutions. We are confident that this partnership will help us ensure high quality in the transformation process and that our solutions reach as many users as possible.

Thanks to increased sales, strong partnerships, and innovative solutions, we are now facing a bright future with continued growth and opportunities. I would like to extend my heartfelt thanks to all our employees, partners, and shareholders for your commitment and support – together, we are making a real difference.

Thank you for being part of our journey.

Anders Segerström
Chief Executive Officer, iZafe Group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Interim Report Q3 2024

CEO-interview

Kvartalsrapport Bild

iZafe Group Celebrating a milestone: Dosell makes its grand debut in Spain with Ti Medi partnership

iZafe Group AB (“iZafe Group”) is thrilled to announce the grand launch of Dosell in collaboration with Ti Medi, taking place in Granada on October 22-23. The event marks a pivotal moment as Ti Medi introduces its innovative concept, combining the Savioo Website and Dosell medication dispenser, to the Spanish market. Attendees at the event include 150 Ti Medi's customers, who will gain exclusive insights into Dosell and its transformative impact on medication adherence. Ti Medi's extensive network includes around 1,400 pharmacies, which significantly expanding the potential reach and impact of this innovative concept.

This launch paves the way for Dosell to become commercially available in Spain, with the first active units expected to be operational shortly. The collaboration between iZafe Group and Ti Medi represents a breakthrough in addressing the critical need for efficient and reliable medication management. The event highlights the tireless efforts and commitment of both teams in bringing this solution to life.

“We are incredibly proud to see the result of months of hard work and dedication as Dosell is now launched in Spain. This is a significant milestone, not only for iZafe Group but for the entire healthcare sector in Spain. Dosell will make a substantial difference in patients’ lives by simplifying their medication management. The launch also serves as strong proof of our successful partnership with Ti Medi, and we look forward to following Dosell’s impact on the Spanish market,” says Anders Segerström, CEO of iZafe Group.

The event in Granada serves as the official introduction of Dosell to Ti Medi's extensive network of clients, showcasing its potential to revolutionize medication adherence through an integrated system. The comprehensive approach, which includes Ti Medi's packaging technology alongside Dosell, empowers pharmacies to monitor patients’ adherence with unprecedented efficiency.

Marc Tarruell Tibau, CEO of Ti Medi, adds, “Bringing Dosell into our solution portfolio is a game changer. Our customers will now be able to offer an all-in-one package that significantly enhances medication management. This integration is a key step forward in improving adherence and, ultimately, patient outcomes.”

With Dosell now available on the Spanish market, iZafe Group is poised to continue expanding its footprint in Europe, with Spain set to become one of the key markets for the company's innovative healthcare solutions.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group Celebrating a milestone: Dosell makes its grand debut in Spain with Ti Medi partnership

Dosell Spanien

iZafe Group AB and Randstad Partner in Norway to Transform Medication Management and Drive Cost Savings for Municipalities

iZafe Group AB ("iZafe Group") today announces a strategic partnership with Randstad, a global leader in healthcare personnel services, to launch a new initiative in Norway. This collaboration aims to ensure the long-term and effective implementation of Dosell's medication dispensers across Norwegian municipalities by providing the right personnel with comprehensive training and ongoing support.

As part of our relaunch in Norway, we recognize that the most critical factor for success is effective implementation. Randstad will play a central role in managing significant parts of this implementation, regardless of which partner in Norway sells Dosell.

With the increasing demand for efficient medication management in healthcare systems, Dosell's partnership with Randstad combines technological innovation with human expertise. Randstad's strong presence in nearly all municipalities in Norway allows for tailored staffing solutions and professional development programs, ensuring that healthcare professionals are fully trained to use Dosell's cutting-edge medicine dispenser. The initiative aims to enhance patient safety and optimize medication management throughout Norway's healthcare sector.

"We are very excited to launch this partnership with Randstad in Norway, a country where we see great potential for improving medication management through our technology," says Anders Segerström, CEO of iZafe Group. "By collaborating with Randstad, which has an extensive network and deep understanding of the local healthcare landscape, we can ensure that our medicine dispenser is implemented effectively and sustainably across Norwegian municipalities. This partnership is about combining the best technology with the right people to deliver long-term, high-quality healthcare solutions."

Per Arne Lien, Manager of Health Technology at Randstad, commented, "Our extensive presence in the majority of the municipalities in Norway allows us to uniquely understand the local needs and challenges of healthcare providers. Partnering with Dosell enables us to support Norwegian municipalities with experienced, well-trained professionals who can ensure the successful integration and long-term use of Dosell's medicine dispenser. Together, we are committed to advancing healthcare quality and patient outcomes in Norway through innovation and expertise."

The partnership will begin with a pilot program across several municipalities in Norway, focusing on delivering comprehensive training for healthcare professionals and providing continuous support and advisory services. This approach ensures that Dosell's technology is not only effectively implemented but also continuously optimized to meet the evolving needs of healthcare providers and their patients.

About Randstad
Randstad is a global leader in HR services, specializing in staffing, talent management, and workforce solutions. In Norway, Randstad has a significant presence across nearly all municipalities, providing skilled professionals to support local healthcare services and other sectors.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group AB and Randstad Partner in Norway to Transform Medication Management and Drive Cost Savings for Municipalities

Randstad Care

iZafe Group introduces a groundbreaking tripartite collaboration aimed at enhancing independence and safety in medical care

iZafe Group AB ("iZafe Group") today announces a strategic tripartite collaboration with Zafe Care Systems AB and Sensorem AB. This partnership, building on previous successes in municipal care, represents a significant step forward in providing users with increased independence and safety in their medication management, regardless of their location.

Dosell has already established itself as a leading solution for safe and efficient medication management. By automating the dosing and distribution of medications, Dosell reduces the risk of taking the wrong medication, double dispensing, and frees up valuable time for healthcare staff. Now, with the integration of Sensorem’s mobile safety alarm, the next step is being taken to offer a holistic solution that places the user’s freedom and safety at the forefront.

The Sensorem watch not only serves as a reminder to take medications, such as insulin, but also functions as a mobile safety alarm that is constantly present. If a user is far from home and does not take their medication on time, an alert is sent directly to the watch, ensuring that the appropriate actions can be taken immediately. This creates a unique combination of security and independence, allowing the user to live an active life without worrying about their health.

“With this collaboration between iZafe Group, Zafe Care Systems, and Sensorem, we are offering not just a solution for safe medication management, but also a new level of independence and security for users. Our vision is for our products to be easily integrated and become part of a comprehensive solution, showcasing the strength of Dosell. By developing products and services that can seamlessly interact with other systems, we aim to create the best possible solution for both users and healthcare professionals, without the need to manage multiple apps and systems,” says Anders Segerström, CEO of iZafe Group AB.

Per la Fleur, CEO of Zafe Care Systems AB, adds: “By combining Dosell’s reliability with Sensorem’s mobile safety alarm, we are creating an unbeatable solution that not only improves the quality of care but also gives the user the freedom to live an independent life. This is the future of healthcare technology, and we are proud to be part of this development.”

Bobo Delemark, CEO of Sensorem AB, emphasizes: “The Dosell medication dispenser and Sensorem’s mobile safety alarm together form a unique combination that is beneficial for both the user and the municipality. The user can, for example, be in a different location and be notified that medication needs to be taken (both verbally and in text), and healthcare staff can initially call the mobile alarm to ensure the medication is taken.”

About Zafe Care Systems AB: Zafe Care Systems AB specializes in developing technological solutions for healthcare and social care. With a focus on user-friendliness and safety, Zafe delivers innovative products that improve the quality of care and increase the independence of users. www.zafe.se

About Sensorem: Sensorem develops mobile safety alarms and security solutions that provide users with increased safety and freedom in their daily lives. By combining advanced technology with ease of use, Sensorem offers products that are both reliable and flexible. https://www.sensorem.com/sv/

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group introduces a groundbreaking tripartite collaboration aimed at enhancing independence and safety in medical care

Klocka På Arm 2